Antibody fragment (Fc)

[{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b9a/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b9a/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b99/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b99/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b98/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b98/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b97/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b97/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b96/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b96/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b95/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b95/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b94/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b94/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b93/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b93/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b92/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b92/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b91/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b91/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b90/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b90/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b8f/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b8f/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b8e/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b8e/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5c264d9ac405e91300bc0b8d/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5c264d9ac405e91300bc0b8d/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5d9e4006efa5a70004f845ce/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5d9e4006efa5a70004f845ce/5c264d21c405e91300bc0b8c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5d9e4006efa5a70004f845cd/5c264d21c405e91300bc0b8c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5d9e4006efa5a70004f845cd/5c264d21c405e91300bc0b8c.png"}]